May 23, 2011

The U.S. Food and Drug Administration today approved Vertex’s Incivek, also known as telaprevir, a potential blockbuster drug to treat chronic hepatitis C infection. Developed by Cambridge-based Vertex Pharmaceuticals, the drug is used for patients who have either not received interferon drug therapy for their infection or who have not responded adequately to other treatments. […]

View PDF

May 6, 2011

Vertex Pharmaceuticals finalized a deal yesterday to move its offices to the Fan Pier development on the South Boston Waterfront. A company spokesman said Vertex will pay an average of 72.5 million in annual rent for 1.1 million square feet of office and lab space over the next 15 years.

View PDF
article on Vertex Makes Billion-dollar Bet On Fan Pier Site

May 6, 2011

Vertex Pharmaceuticals has signed a $1.1 billion, 15-year lease to move its headquarters from Cambridge to South Boston’s waterfront – a big boost for Hub Mayor Thomas M. Menino’s planned “Innovation District.”

View PDF

May 5, 2011

Cambridge, MA-based Vertex Pharmaceuticals will be known as Boston-based Vertex Pharmaceutics in the not so distant future. The biotech company said today it has signed a 15-year lease to occupy new labs and offices being built at Boston’s Fan Pier, according to a regulatory filing.

View PDF

May 5, 2011

It’s been a long six years for Joe Fallon and his dreams for the South Boston waterfront, but these days the developer’s on a roll with butter on his back. As of Thursday morning, Fallon said he was already plotting to advance the second stage of development at his sprawling, 21-acre project site on Fan […]

View PDF
press release Vertex Signs Boston Lease

May 5, 2011

Cambridge, MA-based Vertex Pharmaceuticals will be known as Boston-based Vertex Pharmaceuticals in the not so distant future. The biotech company said today it has signed a 15-year lease to occupy new labs and offices being built at Boston’s Fan Pier.

View PDF
Big Science

May 1, 2011

The Fallon Company’s Fan Pier development may include an 1800-employee headquarters from Vertex Pharmaceutics, which has signed a non-binding letter of intent for the project, pending final FDA approval of a strong drug candidate for the treatment of hepatitis C.

View PDF
archive.php